We are live on ! Find out more
ELI

ELITE PHARMACEUTICAL
ELI

Delisted

ELI was delisted on the 20th of May, 2009.

Back to rankings

3 hedge funds and large institutions have $15.9K invested in ELITE PHARMACEUTICAL in 2019 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more capital invested

Capital invested by funds: $8.49K → $15.9K (+$7.45K)

50% more funds holding

Funds holding: 2 → 3 (+1)

Holders
3
Holders Change
+1
Holders Change %
+50%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CFG
Citizens Financial Group
Rhode Island
+$5K

Top Sellers

No sellers this quarter

ELI Hedge Fund Activity: Q1 2019 in Review

3 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in ELITE PHARMACEUTICAL (ELI) for Q1 2019, worth a combined $15.9K — up 88% from $8.49K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new ELI positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.

The largest buyer was Citizens Financial Group, opening a new position worth an estimated $5K.

  • 3 institutional investors held ELITE PHARMACEUTICAL (ELI) as of Q1 2019, up from 2 in Q4 2018.
  • Funds reported $15.9K of ELITE PHARMACEUTICAL stock for Q1 2019, up 88% quarter-over-quarter.
  • 1 fund opened new ELITE PHARMACEUTICAL positions in Q1 2019 and 0 closed out, a net change of +1 holder.
  • The largest ELITE PHARMACEUTICAL buyer in Q1 2019 was Citizens Financial Group, an estimated $5K added.

Based on aggregated 13F filings for Q1 2019.